While the company gained overall, its orthopedics business suffered, and CEO Olivier Bohuon said the company will be taking steps to reduce a cost base in orthopedics that is too high for ongoing market conditions. The company’s orthopedic business reported $548 million, only a 3 percent increase over the third quarter of last year.
The orthopedic reconstruction business grew by 2 percent, offset by a 2 percent decrease in the hip business. The knee and trauma businesses carried the orthopedics business, growing by 6 percent and 4 percent respectively. The company’s endoscopy business grew by 7 percent to $226 million.
Related Articles on Orthopedic Device Companies:
Lanx Names Dr. Ryan DenHaese Medical Education Director for New Training Program
LDR Receives FDA Clearance for Oblique ALIF Cage
Globus Medical Highlights 4 New Spine Devices
